Muna Therapeutics ApS has patented triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of osteoporosis, rheumatoid arthritis, systemic lupus ...

Like waves crashing on the beach, med-tech IPOs keep on coming. Heartflow Inc. set terms for its IPO on Aug. 1, offering 12.5 ...

Sava Technologies Ltd. raised $19 million in a series A funding round for its multi-molecule biosensor platform that can detect biomarkers just beneath the skin, in real-time. The funds will go ...

While U.S. President Donald Trump’s country-by-country reciprocal and newly negotiated tariffs go into effect today, a separate, global biopharma sector tariff of, possibly, 200% continues to loom ...

Chinese scientists have discovered a common mechanism by which structurally distinct proteins elicit an allergic reaction, showing they cause the formation of pores in epithelial airway cells. That ...

The U.S. Department of Justice announced July 31 that Illumina Inc. agreed to pay $9.8 million to settle allegations it sold ...

GSK plc scientists have presented findings from studies on the therapeutic potential of GSK-5862611, an anti-Sortilin ...

Nonprofit dealmaking in biopharma has been limited in 2025, with total disclosed value reaching just $99.7 million through ...

With the U.S. FDA’s approval of Lenz Therapeutics Inc.’s Vizz (aceclidine ophthalmic solution), there is a third eye drop on ...

Prognosis is extremely poor for patients with head and neck squamous cell carcinoma (HNSCC), which accounts for around 90% of all head and neck cancer. Especially in the more aggressive subtype of ...

Bristol Myers Squibb Co. has prepared and tested proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to interleukin-1 receptor-associated kinase 4 ...